 | |
- close
- close
|
Business Wire
Nov 2
Comment
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its
Red Orbit
Oct 20
Comment
Genetic information from an extinct species of bison preserved in permafrost for thousands of years could help improve modern agricultural livestock and breeding programs, according to University of Adelaide researchers.Researchers from the...
Business Wire
Oct 20
Comment
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at
Stock Blog Hub
Oct 16
Comment
Biovail Corporation (BVF) recently provided an update on its development plans for pimavanserin for Parkinson’s disease psychosis (PDP). The company is developing the candidate in collaboration with Acadia Pharmaceuticals, Inc. (ACAD) and stated...
StreetInsider.com
Oct 15
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/ACADIA+Pharma+%28ACAD%29+to+Cut+Workforce+by+50%25/5021396.html for the full story.
Business Wire
Oct 6
Comment
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at
Business Wire
Oct 6
Comment
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase
StreetInsider.com
Sep 2
Comment
Visit StreetInsider.com at http://www.streetinsider.com/FDA/Dead-Cat-Bounce+In+ACADIA+%28ACAD%29/4916666.html for the full story.
Market Intelligence Center
Sep 1
Comment
Acadia (ACAD) was downgraded today by analysts at Citigroup and the stock is now at $1.93, down $3.91 (-66.95%) on volume of 30,617,696 shares traded. The analysts downgraded the stock to Sell from Hold. Over the last 52 weeks the stock has ranged...
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
ACAD AT A GLANCE
References
| ||||||
|
|
